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Abstract 
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in 
single populations, with the majority of reports focused on Caucasians in Europe and North America. 
The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 
families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers 
in 49 countries on 6 continents. This study comprehensively describes the characteristics of the 1,650 
unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the 
CIMBA database. We observed substantial variation in mutation type and frequency by geographical 
region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency 
were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and 
which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the 
population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for 
genetic testing and may justify a more broad-based oncogenetic testing in some populations. 
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BACKGROUND 
Women who carry germline mutations in either BRCA1 [OMIM 113705] or BRCA2 [600185] are at a 
greatly increased risk of breast and ovarian cancers. Estimates of cancer risk associated with BRCA1 
and BRCA2 mutations vary depending on the population studied. For mutations in BRCA1, the 
estimated average risk of breast and ovarian cancers ranges from 57-65% and 20-50%, respectively 
(Chen and Parmigiani, 2007; Kuchenbaecker, et al., 2017). For BRCA2, average risk estimates range 
from 35-57% and 5-23%, respectively (Chen and Parmigiani, 2007; Kuchenbaecker, et al., 2017). 
Mutation-specific cancer risks have been reported that suggest breast cancer cluster regions (BCCR) 
and ovarian cancer cluster regions (OCCR) exist in both BRCA1 and BRCA2 (Kuchenbaecker, et al., 
2017; Rebbeck, et al., 2015). The identification of mutations in BRCA1 or BRCA2 has important clinical 
implications, as knowledge of their presence is important for risk assessment and informs medical 
management for patients. Interventions, such as risk-reducing bilateral mastectomy and salpingo-
oophorectomy or annual breast MRI screening, are available to women who carry deleterious BRCA1 
or BRCA2 mutations to enable early detection of breast cancer and for active risk reduction by risk-
reducing surgery (Domchek, et al., 2010; Rebbeck, et al., 2002; Saslow, et al., 2007). The presence of 
BRCA1 or BRCA2 mutations also can influence cancer treatment decisions, principally around the use 
of platinum agents or poly (ADP-ribose) polymerase (PARP) inhibitors (Lord and Ashworth, 2017) or 
contralateral risk-reducing mastectomy. Increasing numbers of women are having clinical genetic 
testing for BRCA1 and BRCA2 mutations, and recommendations continue to expand to whom testing 
should be offered (NCCN, 2017).  
 
In whites drawn from the general populations in North America and the United Kingdom, the prevalence 
of BRCA1 and BRCA2 mutations has been estimated around a broad range from 0.1-0.3%, and 0.1-
0.7%, respectively (Peto, et al., 1999; Struewing, et al., 1997; Whittemore, et al., 2004).  The Australian 
Lifepool study, studying a control population consisting of cancer-free women ascertained via 
population-based mammographic screening program, estimated the overall frequency of BRCA1 and 
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BRCA2 mutations to be 0.65% (1:153), with BRCA1 mutations at 0.20% (1:500) and BRCA2 mutations 
at 0.45% (1:222) (Thompson, et al., 2016).  Estimates from the Exome Aggregation Consortium (ExAC) 
are similar, with frequencies of BRCA1 and BRCA2 mutations (excluding The Cancer Genome Atlas 
(TCGA) data) at 0.21% (1:480) and 0.31% (1:327), respectively; or combined at 0.51% (1:195) 
(Maxwell, et al., 2016).  As they do not include large genomic rearrangements, some newer population-
based estimates may still under-represent the total number of BRCA1 and BRCA2 mutations.  Although 
the overall prevalence of BRCA1 and BRCA2 mutations in most general populations is low, many 
hundreds of thousands of yet-to-be-tested individuals worldwide carry these mutations.  
The prevalence of founder mutations in some racial/ethnic groups is much higher. For example, the 
mutations BRCA1 c.5266dup (5382insC), BRCA1 c.68_69del (185delAG) and BRCA2 c.5946del 
(6174delT), have a combined prevalence of 2-3% in U.S. Ashkenazi Jews (Roa, et al., 1996; 
Struewing, et al., 1997; Whittemore, et al., 2004). For these mutations, double heterozygotes in BRCA1 
and BRCA2 also have been reported (Friedman, et al., 1998; Moslehi, et al., 2000; Ramus, et al., 
1997a; Rebbeck, et al., 2016). Several other founder mutations have been identified, including the 
Icelandic founder mutation BRCA2 c.771_775del (999del5) (Thorlacius, et al., 1996); the French 
Canadian mutations BRCA1 c.4327C>T (C4446T), and BRCA2 c.8537_8538del (8765delAG) (Oros, et 
al., 2006b; Tonin, et al., 1999; Tonin, et al., 2001); the BRCA1 mutations c.181T>G, and c.4034delA in 
Central-Eastern Europe (Gorski, et al., 2000); the BRCA1 c.548-4185del in Mexico (Villarreal-Garza, et 
al., 2015b; Weitzel, et al., 2013)(Villarreal-Garza, et al., 2015b; Weitzel, et al., 2013), the BRCA2 
mutation c.9097dup in Hungary (Ramus, et al., 1997b; Van Der Looij, et al., 2000) and others. These 
mutations represent the majority of mutations observed in these populations and have been confirmed 
as true founder mutations as they have common ancestral haplotypes (Neuhausen, et al., 1996, 1998; 
Oros, et al., 2006a). Recurrent mutations have been identified in other populations, but they represent a 
smaller proportion of all unique BRCA1 and BRCA2 mutations, and have not been characterized as 
true founder mutations. There are multiple recurrent mutations in Scandinavian, Dutch, French, and 
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Italian populations (Ferla, et al., 2007). Similarly, a number of recurrent mutations specific to non-
European populations also have been reported in Hispanic/Mexican, African-American, Middle Eastern, 
and Asian populations (Bu, et al., 2016; Ferla, et al., 2007; Kurian, 2010; Lang, et al., 2017; Ossa and 
Torres, 2016; Villarreal-Garza, et al., 2015b).  
The mutational spectra in BRCA1 and BRCA2 are best delineated in whites from Europe and North 
America. However, data on mutational spectra in non-white populations of Asian, African, 
Mediterranean, South-American and Mexican Hispanic descent have also been reported (Abugattas, et 
al., 2015; Ahn, et al., 2007; Alemar, et al., 2016; Bu, et al., 2016; Eachkoti, et al., 2007; Ferla, et al., 
2007; Gao, et al., 2000; Gonzalez-Hormazabal, et al.; Ho, et al., 2000; Jara, et al., 2006; John, et al., 
2007; Kurian, 2010; Laitman, et al.; Lang, et al., 2017; Lee, et al., 2003; Li, et al., 2006; Nanda, et al., 
2005; Ossa and Torres, 2016; Pal, et al., 2004; Rodríguez, et al., 2012; Seong, et al., 2009; Sharifah, et 
al.; Solano, et al., 2017; Song, et al., 2005; Song, et al., 2006; Toh, et al., 2008; Torres, et al., 2007; 
Troudi, et al., 2007; Villarreal-Garza, et al., 2015b; Vogel, et al., 2007; Weitzel, et al., 2005; Weitzel, et 
al., 2007; Zhang, et al., 2009). In the current study, we provide a global description of BRCA1 and 
BRCA2 mutations by geography and race/ethnicity from the investigators of the Consortium of 
Investigators of Modifiers of BRCA1/2 (CIMBA). 
 
METHODS 
Details of centers participating in CIMBA and data collection protocols have been reported previously 
(Antoniou, et al., 2007).  Details of the CIMBA initiative and information about the participating centers 
can be found at http://cimba.ccge.medschl.cam.ac.uk/h (Chenevix-Trench, et al., 2007).  All included 
mutation carriers participated in clinical or research studies at the host institutions after providing 
informed consent under IRB-approved protocols. Sixty-nine centers and multicenter consortia 
submitted data that met the CIMBA inclusion criteria (Antoniou, et al., 2007). Only female carriers with 
pathogenic BRCA1 and/or BRCA2 mutations were included in the current analysis. One mutation 
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carrier per family in the CIMBA database was included in this report. The actual family relationships 
(e.g., pedigrees) were not available, but a variable that defined family membership supplied by each 
center was used for this purpose. Less than 1% of families (86 of 29,700) had two family members with 
two different mutations.  In these situations, each mutation observed in the family was included in the 
analysis.  In the case of the 94 dual mutation carriers (i.e., individuals with both BRCA1 and BRCA2 
mutations), one of the two mutations was chosen at random for inclusion in the analysis.  
 
The CIMBA data set was used to describe the distribution of mutations by effect and function. For the 
remaining analyses, mutations were excluded if self-reported race/ethnicity data were missing. 
Pathogenicity of mutation was defined as follows: 1) generating a premature termination codon (PTC), 
except variants generating a PTC after codon 1854 in BRCA1 and after codon 3309 of BRCA2; 2) large 
in-frame deletions that span one or more exons; and 3) deletion of transcription regulatory regions 
(promoter and/or first exon) expected to cause lack of expression of mutant allele. We also included 
missense variants considered pathogenic by using multifactorial likelihood approaches (Bernstein, et 
al., 2006; Goldgar, et al., 2004). Mutations that did not meet the above criteria but have been classified 
as pathogenic by Myriad Genetics, Inc. (Salt Lake City, UT) also were included. Classification of 
nonsense-mediated decay (NMD) was based on in-silico predictions and was not based on molecular 
classification (Anczukow, et al., 2008).  
 
Contingency table analysis using a chi-square test was used to test for differences in dichotomous 
variables, as was a t-test for continuous variables. Mutation counts are presented as the number of 
families with the mutation. Fisher’s exact tests were used if sample sizes in any contingency table cell 
were less than five. Analyses were done in STATA, v. 14.2.  
 
RESULTS  
Mutations in BRCA1 and BRCA2 
  14 
From the 26,861 BRCA1 and 16,954 BRCA2 mutation carriers in the CIMBA data set as of June 2017, 
18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations were studied to 
count only one occurrence of a mutation per family. Figure 1 shows the countries that contributed 
mutations to this report. From among these families, 1,650 unique BRCA1 and 1,731 unique BRCA2 
mutations were identified. The unique mutations and number of families in which each mutation was 
observed are listed in Supplementary Table 1. In each gene, the five most common mutations 
(including founder mutations) accounted for 33% of all mutations in BRCA1 (8,739 of 26,861 mutation 
carriers) and 19% of all mutations in BRCA2 (3,244 of 16,954 mutation carriers). A web site containing 
information about the most common mutations reported here can be found at: 
http://apps.ccge.medschl.cam.ac.uk/consortia/cimba/.  This information may be periodically updated as 
new data become available. 
 
Mutation Type and Effect  
Table 1 presents a summary of the type of BRCA1 or BRCA2 mutations and their predicted effect on 
transcription and translation. The most common mutation type was frameshift followed by nonsense. 
The most common effect of BRCA1 and BRCA2 mutations was premature translation termination and 
most of the mutant mRNAs were predicted to undergo nonsense-mediated mRNA decay (NMD) 
(Anczukow, et al., 2008). Despite having the same spectrum of mutations in BRCA1 and BRCA2, the 
frequency distribution by mutation type, effect, or function differed significantly (p<0.05) between 
BRCA1 and BRCA2 mutation carriers for many groups, as shown in Table 1. These observed 
differences are largely because genomic rearrangements and missense mutations account for a much 
higher proportion of mutations in BRCA1 when compared with BRCA2, as previously described 
(Welcsh and King, 2001). 
 
We and others have found that breast (BCCR) and ovarian (OCCR) cancer cluster regions exist that 
may confer differential cancer risks (Gayther, et al., 1997; Gayther, et al., 1995; Kuchenbaecker, et al., 
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2017; Rebbeck, et al., 2015). Figure 2 reports the relative frequency of mutations in the BCCR and 
OCCR by race/ethnicity. Compared with whites, we observed differences in the relative frequency of 
mutations in the BRCA1 BCCR and OCCR in Asians and Hispanics, and in the BRCA2 OCCR in 
Hispanics.  To the degree that the mutations within the BCCRs and OCCRs conferred differential 
cancer risks, these data suggest that BRCA1 and BRCA2 mutation-associated cancer risks may vary 
by race/ethnicity. 
 
Geography and Race/Ethnicity 
The most common mutations by country are summarized in Table 2 (BRCA1) and Table 3 (BRCA2). 
The locations of the mutations that were observed in African American, Asian, and Hispanic 
populations are depicted in Figure 3 (BRCA1) and Figure 4 (BRCA2). Some countries (Albania, 
Bosnia, Costa Rica, Ireland, Honduras, Japan, Norway, Peru, Philippines, Qatar, Saudi Arabia, 
Romania, Venezuela and Turkey) contributed fewer than 10 mutation carriers to the CIMBA database. 
Many of these mutations were submitted to the central database by CIMBA centers that ascertained 
these patients, but these patients originated from a different country. Based on such small numbers, it 
was impossible to make inferences about the relative importance of mutations in these locations.  A 
description of the major ethnicity by country is provided in Supplementary Table 2. 
 
The mutational distribution among the major racial/ethnic groups and by geography are summarized in 
Tables 4 and 5. Table 4 includes only those individuals for whom self-identified race/ethnicity was 
recorded. Note that in some countries it is prohibited to collect data on race and ethnicity, so this 
information is missing.  Among the 10 most common BRCA1 mutations in each racial/ethnic group, a 
few were seen in several populations, including the recurrent Jewish and Eastern European founder 
mutations c.5266dup (5382insC) and c.68_69del (185delAG); c.815_824dup in African-Americans and 
Hispanics; c.3756_3759del in Caucasian and Jews; and c.5503C>T and c.3770_3771del in Asians and 
Jews. Similarly, recurrent mutations in BRCA2 included c.5946del (6174delT) in whites and Jews; 
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c.2808_2811del in whites, African Americans, Asians, Hispanics, and Jews; c.6275_6276del in whites 
and Hispanics; c.3847_3848del in whites and Jews; c.658_659del in African Americans and Hispanics; 
and c.3264dup in Hispanics and Jews. The majority of other recurrent BRCA1 and BRCA2 mutations 
were only observed within a single racial/ethnic group, particularly African Americans, Asians, and 
Hispanics. Of note, the vast majority of women who self-identified as Jewish carry the Ashkenazi 
Jewish founder mutations BRCA1 c.5266dup and c.68_69del and BRCA2 c.5946del. Only 72 (3.9%) of 
1,852 BRCA1 mutation carrier families and 55 (5.6%) of 990 BRCA2 mutation carrier families who self-
identified as being Jewish carried other (non-founder) mutations. However, since many individuals of 
self-identified Jewish ancestry are only tested for the three founder mutations, this number is likely to 
be underestimated. 
 
In African Americans, the majority of BRCA1 mutations were not observed in any other racial/ethnic 
group, implying these mutations may be of African origin. In Hispanics, the most common BRCA1 
mutations also were observed among individuals from other regions who did not self-identify as 
Hispanic, including BRCA1 c.3331_3334del (also observed in Australia, Europe, USA, and the UK), 
and BRCA1 c.68_69del (the Jewish founder mutation) (Weitzel, et al., 2013; Weitzel, et al., 2005).  The 
BRCA1 c.815_824dup mutation has been reported as being of African origin, but has also been 
reported as a recurrent mutation in Mexican-Americans, perhaps as a reflection of the complex 
continental admixture of this population (Villarreal-Garza, et al., 2015b). BRCA1 c.390C>A and 
c.5496_5506delinsA were most commonly found in the Asian population. In BRCA2, c.2808_2811del 
was found among the 10 most frequent mutations in all races/ethnicities. 
 
Recurrent Mutations 
As expected, the most common mutations in the entire data set were the founder mutations BRCA1 
c.5266dup (5382insC), BRCA1 c.68_69del (185delAG), and BRCA2 c.5946del (6174delT). In part, the 
high frequency of these mutations is a consequence of panels that facilitate testing for these three 
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mutations in women of Jewish descent. However, these two BRCA1 mutations also are relatively 
common in regions with a low proportion of individuals who self-identify as Jewish (e.g., Hungary, 
Czech Republic, France, Germany, Italy, Poland Spain, Russia, and UK). BRCA1 c.5266dup is a 
founder mutation thought to have originated 1800 years ago in Scandinavia/Northern Russia, entering 
the Ashkenazi-Jewish population 400-500 years ago, and thus has origins and a spread pattern 
independent of the Ashkenazim (Hamel, et al., 2011). Haplotype studies have been used to determine 
the origin of BRCA1 c.68_69delAG in populations not considered to have a high proportion of Jewish 
ancestry. In some populations, such as the Hispanics in the USA and Latin American, it is associated 
with the Ashkenazi Jewish haplotype, presumably due to unrecognized (Jewish) ancestry (Ah Mew, et 
al., 2002; Velez, et al., 2012; Weitzel, et al., 2005). In other populations, such as Pakistani and 
Malaysians, where BRCA1 c.68_69del is a recurrent mutation, it appears to have arisen independently, 
as it is carried on a distinct haplotype (Kadalmani, et al., 2007; Rashid, et al., 2006). A different 
haplotype was also reported for several British families (the ‘Yorkshire haplotype’) that is distinct from 
both the Jewish and the Indian-Pakistani haplotypes (Laitman, et al., 2013; Neuhausen, et al., 1996).  
 
The only locations in which these three founder mutations were not commonly observed were Belgium 
and Iceland. Iceland has another founder mutation (i.e., BRCA2 c.771_775del).  Yet other founder 
mutations included BRCA1 c.4327C>T and BRCA2 c.8537_8538del in Quebec. This latter mutation in 
BRCA2 also is the most common mutation in high-risk families in Sardinia (Pisano, et al., 2000) and 
was also reported in a few Jewish Yemenite families, with a distinct haplotype(Palomba, et al., 2007). 
The BRCA1 c.181T>G mutation was observed in Central Europe (Austria, Czech Republic, Germany, 
Hungary, Italy and Poland), but also observed in the US, Argentina, Latvia, Lithuania and Israel. This 
mutation has been found on a common haplotype in individuals of Polish and Ashkenazi Jewish 
ancestry, suggesting it is an Eastern European founder mutation (Kaufman, et al., 2009).  The large 
rearrangement mutation in BRCA1 c.548-?4185+?del (ex9-12del) appears to be an important founder 
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mutation in Mexico, with findings of a common haplotype and an estimated age at 74 generations 
(~1,500 years) (Weitzel, et al., 2013). 
 
We observed a number of other recurrent mutations. BRCA1 c.3331_3334del comprised more than half 
of all mutations identified in Colombia, consistent with a previous report that this is a founder mutation 
in the Colombian population (Torres, et al., 2007). However, this mutation has not been found at high 
rates in a second Colombian population (Cock-Rada, et al., 2017). BRCA2 c.2808_2811del was 
frequently observed, not only as the most common mutation in France and Colombia, but also in other 
Western and Southern European countries, and destinations to which individuals from these countries 
have migrated. It estimated to have arisen approximately 80 (46-134) generations ago. However, due 
to the diversity of the haplotypes, multiple independent origins could not be ruled out (Neuhausen, et 
al., 1998). BRCA2 c.6275_6276del was a recurrent BRCA2 mutation in Australia, the UK, Belgium, 
Spain, the Netherlands, and North America. This mutation has been estimated to have originated 52 
(24-98) generations ago from a single founder (Neuhausen, et al., 1998). Recurrent or founder 
mutations were observed in diverse populations. For example, the c.115T>G (Cys39Gly) mutation has 
been described in Greenlanders (Hansen, et al., 2009).  The c.2641G >T and c.7934del mutations 
have both been reported as founder mutation in South African Afrikaners (Reeves, et al., 2004).  
 
DISCUSSION  
We have reported worldwide distribution of BRCA1 and BRCA2 mutations curated in the CIMBA 
dataset. These results may aid in the understanding of the mutation distribution in specific populations 
as well as imparting clinical and biological implications for our understanding of BRCA1- and BRCA2-
associated carcinogenesis.  
 
Clinical testing for BRCA1 and BRCA2 mutations has benefited substantially from knowledge about 
common mutations in specific populations. In many countries, the three Ashkenazi-Jewish founder 
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mutations are offered as a mutation testing panel for self-reported Ashkenazim, based on their 
frequency. This approach is much less expensive than comprehensive gene sequencing. The 
identification of commonly-occurring mutations in other populations could lead to more efficient and 
cost-effective mutation testing for BRCA1 and BRCA2.  For example, Villareal-Garza et al. (Villarreal-
Garza, et al., 2015a) have developed the HISPANEL of mutations that optimizes testing in 
Hispanic/Latino populations. In the present study, we have identified mutations that may exist at a 
sufficient prevalence to warrant consideration for population-specific mutation testing panels. Criteria 
for developing such panels for BRCA1 and BRCA2 mutation screening are not available. However, 
mutations that are in a specific population and that capture a sufficient percentage of mutations in high 
risk individuals and families in that population may be appropriate for use in targeted genetic testing. 
Before such panels can be developed, population-based studies of mutation frequency in specific 
populations should be undertaken. The data reported herein provide a list of the recurrent mutations 
around which such panels could be developed, but the frequencies are not population-based, 
particularly in settings where founder mutations are preferentially screened (e.g., the Jewish founder 
panels). Similarly, putative founder mutations identified by assessing common ancestral origins of 
specific mutations (rather than just high prevalence; Table 5) may form the basis of population-specific 
BRCA1 and BRCA2 mutation screening panels. 
 
We report the distribution of BRCA1 and BRCA2 mutations in nearly 30,000 families of bona-fide 
disease-associated mutations. The strengths of this report include the large sample size that reflects a 
geographically and racially/ethnically diverse set of BRCA1 and BRCA2 mutation carriers. However, 
some limitations need to be considered. First, the sample set presented here does not reflect a 
systematic study of these populations or races/ethnicities; the data reflect patterns of recruitment (e.g., 
individuals with higher risk or prior diagnosis of cancer who consented to participate in research 
protocols) that contributed to the CIMBA consortium. Certain racial/ethnic or socio-demographic groups 
are under- or over-represented or missing in our data set and, as a consequence, mutations may be 
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over- or under-represented. For example, the existence of a commercial panel of three Jewish founder 
mutations enhances genetic testing for those mutations. As a result, the most frequently observed 
mutations in some populations (e.g., the USA) reflect the widespread use of this testing panel in the 
USA population. Similar arguments may also apply for other populations, where testing for certain 
founder mutations may be more frequent.  Therefore the relative frequencies of mutations by population 
in the present study may be subject to such testing biases. Comparing the relative frequencies is also 
complicated by the inclusion of related individuals.   
 
Second, although the CIMBA data represent most regions around the world, there are limitations 
related to which groups of individuals have been tested and which centers contributed data. In 
particular, non-white ancestry populations are still under-represented in research reports of mutation 
spectrum and frequency. Genetic testing in the developing world remains limited.  
 
Third, we presented the mutations in terms of type or effect (Table 1), but these designations are not 
always based on experimental evidence. For example, NMD mutation status is almost always defined 
by a prediction rule rather than in vitro experiments that confirm the presence of nonsense mediated 
decay.  
 
Fourth, we presented the occurrence of putative founder mutations. Some of these founder mutations 
(e.g., BRCA1 c.68_69del, BRCA2 c.771_775del) have been demonstrated to be true founder mutations 
based on actual ancestry analyses. Others, however, have only been identified as occurring commonly 
in certain populations, but haplotype or similar analyses of founder status may not have been done.  
 
Fifth, our analysis was based on self-reported race/ethnicity of study participants, but this information 
may misclassify some groups of individuals. For example, some Middle Eastern groups may have been 
classified as “Caucasian” based on the data available, but in fact may represent a distinct group that 
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was not captured here. Moreover, in some large centers participating in CIMBA, collecting information 
on race/ethnicity is prohibited and these mutation carriers were excluded from the comparisons.  
 
Finally, we evaluated mutations by racial/ethnic and geographic designations, but some of these may 
be misclassified. For example, while BRCA1 c.68_69del has been shown to arise independently of the 
Jewish founder mutation in Pakistan (Rashid, et al., 2006), we cannot determine if the identified group 
also contains some Ashkenazi Jewish individuals. 
 
The data presented herein provide new insights into the worldwide distribution of BRCA1 and BRCA2 
mutations. The identification of recurrent mutations in some racial/ethnic groups or geographical 
locations raises the possibility of defining more efficient strategies for genetic testing. Three Jewish 
founder mutations BRCA1 c.5266dup (5382insC) and BRCA1 c.68_69del (185delAG) and BRCA2 
c.5946del (6174delT) have long been used as a primary genetic screening test for women of Jewish 
descent. The identification here of other recurrent mutations in specific populations may similarly 
provide the basis for other mutation-specific panels. For example, BRCA1 c.5266dup (5382insC) may 
be a useful as a single mutation screening test in Central-Eastern European populations before 
undertaking full sequencing. However, this basic test may be supplemented with screening for BRCA1 
c.181T>G, as the second most common mutation of the region, and for some special cases, to include 
most common Hungarian BRCA2 founder mutation c.9097dup (9326insA) for those with Hungarian 
ancestry (van der Looij, et al., 2000, Ramus, et al., 1997b). In Iceland, only two mutations were 
reported: the founder mutation BRCA2 c.771_775del and the rarer BRCA1 c.5074G>A (Bergthorsson, 
et al., 1998). A number of other situations can be identified in which specific mutations explain a large 
proportion of the total mutations observed in a population. These and other such examples suggest that 
targeted mutation testing panels which include specific mutations could be developed for use in specific 
populations. Finally, we focused on female BRCA1 and BRCA2 mutation carriers in this report. 
However, the growing knowledge about BRCA1 and BRCA2-associated cancers in men, particularly 
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prostate cancer (Ostrander and Udler, 2008; Pritchard, et al., 2016), suggests that the information 
presented herein will also have value in genetic testing of men. 
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